APLI.TO - Appili Therapeutics Inc.
| Previous Close | 0.0400 |
| Open | 0.0350 |
| Bid | 0.0350 x N/A |
| Ask | 0.0400 x N/A |
| Day's Range | 0.0350 - 0.0400 |
| 52 Week Range | 0.0300 - 0.0750 |
| Volume | |
| Avg. Volume | 70,996 |
| Market Cap | 4.851M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Jun 27, 2023 - Jul 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.20 |
Business WireAppili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
HALIFAX, Nova Scotia, May 24, 2023--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office ("USPTO") has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled "Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same". The p
Business WireAppili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
HALIFAX, Nova Scotia, May 08, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the Company has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program. This contract represents the first stage of funding from the previously announced award from the U.S. Department of Def
Business WireAppili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
HALIFAX, Nova Scotia, April 18, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on April 25 and 26, 2023.
Business WireAppili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
HALIFAX, Nova Scotia, April 03, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer. Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key com
Business WireAppili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
HALIFAX, Nova Scotia, March 20, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement (the "Amended Loan Agreement") with Long Zone Holdings Inc. ("LZH"), amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022 (the "Original Loan
Business WireAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia, February 14, 2023--Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.
- Business Wire
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
HALIFAX, Nova Scotia, February 08, 2023--Appili Therapeutics Inc. (TSX: APLI) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its partner Saptalis Pharmaceuticals LLC ("Saptalis"), announced that the Food and Drug Administration ("FDA") accepted the ATI-1501 New Drug Application ("NDA"). ATI-1501 is Appili’s liquid oral reformulation of the antibiotic metronidazole, which has been licensed to Saptalis. The F
Business WireAppili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
HALIFAX, Nova Scotia, January 17, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, whi
- Baystreet
Stocks in play: Appili Therapeutics Inc.
Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...
Business WireAppili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
HALIFAX, Nova Scotia, January 13, 2023--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that t
Business WireAppili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
HALIFAX, Nova Scotia, November 14, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense ("DOD"), via the Joint Science and Technology Office of the Defense Threat Reduction Agency ("DTRA") in partnership with the U.S. Air Force Academy ("USAFA"), will provide at least US$14 million in funding over two years to fund th
Business WireAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia, November 10, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.
Business WireAppili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, September 22, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.
Business WireAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia, August 12, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.
Business WireAppili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
HALIFAX, Nova Scotia, August 02, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.
Business WireAppili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.